ClinicalTrials.gg
RecruitingNCT06100263B-REPUpdated Feb 10, 2026

Breast Cancer Resiliency Through Exercise Program (B-REP)

An interventional study of Individualized exercise program and Control Arm in Breast Cancer Female, sponsored by University of Michigan Rogel Cancer Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by University of Michigan Rogel Cancer Center · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center — 5 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · University of Michigan Rogel Cancer Center.

Planned enrollment
7th of 36
75 · median 34
Started
2024
with 4 others
No phase
18 of 48
3 open now
Registered
43rd of 48
by date

Among the 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center, this one is the 7th largest by planned enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2024, is one of 18 with no phase, and was the 43rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center, or all of them as a file.
02

Study summary

The study will use a cross-sectional study design with a follow-up 2-arm randomized controlled trial with that has assessments at baseline, post-intervention (i.e., Week 12), and 3-months post-intervention (i.e., Week 24). The 2 arms are the 12-week intervention and waitlist control among 30 Black breast cancer survivors

Read the detailed description

14AUG2025- The sample size was updated, and the questionnaire was split into 2 questionnaires, as a planned solution in response to a low accrual

28OCT2025- Amendment was processed to update design and intervention items. The exercise threshold was changed from a 1-repeition maximum (1RM) to a 5-repeptition maximum (5RM). Since the intervention includes functional exercises, so we elected to use a functional strength (5RM) outcome rather than a maximal strength outcome (1RM) to better align with the intervention. The control condition was changed to a waitlist design. A waitlist control is more engaging, and there is a higher likelihood of retaining control participants.

03

Conditions studied

  • Breast Cancer Female

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Women will be eligible if they meet the following criteria:

  • self-identify as Black or African American or Afro-Latina/e;
  • are ≥18 years old;
  • have a confirmed diagnosis of breast cancer, Stage I to IIIA;
  • have completed primary active treatment (i.e., surgery, chemotherapy, and radiation) within 5 years prior to study start where concomitant hormonal therapy is acceptable;
  • are not meeting current cancer-specific resistance exercise guidelines of ≥ 2 times per week; and
  • are able to speak and understand English.

Exclusion criteria

Exclusion Criteria:

  • disease;
  • medical reason that precludes them from increasing current exercise levels;
  • planned elective surgery during study period;
  • pregnant or plans to become pregnant during the study period;
  • plans to move out of United States during the study period; (the rationale for this exclusion is that it will be difficult to conduct the in-person assessments if a participant leaves the United States);
  • current enrollment in another exercise trial; and/or
  • inability to pass exercise pre-screening or receive physician consent to increase current physical activity levels.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Intervention (Supervised exercise)

    The individualized program is based on participants' baseline 5-repetition maximum muscular strength assessment and is aligned with current cancer-specific exercise recommendations. The resistance program will follow the FITT principle (frequency, intensity, time, and type): Frequency. Participants will aim for 3 resistance exercise sessions per week. Intensity. Resistance exercise intensity will have a schedule for increased progression by both load via increased weight and volume via increased repetitions and sets. If participants are not able to increase resistance loads as scheduled, they will remain at their current load and volume until the next scheduled increase. 50% of 5-repetition maximum for upper and lower body. 3 sets of 8 to 12 repetitions. 60% of 5-repetition maximum for upper and lower body. 3 sets of 8 to 12 repetitions. 70% of 5-repetition maximum for upper and lower body. 4 sets of 8 to 12 repetitions.

    Other: Individualized exercise program

  • Active comparator
    Control (waitlist)

    Participants randomized to the waitlist control condition will be on a waiting list for 24 weeks. Participants in waitlist control condition will complete measures on the same schedule as intervention participants. After 24 weeks, participants will be offered to participate in the online sessions with an exercise trainer using Zoom twice per week for 12- weeks. The sessions will be 30 to 45minutes in length.

    Other: Control Arm

Interventions

  • OtherIndividualized exercise program

    guided exercise program for 12 weeks

  • OtherControl Arm

    Control Arm Waiting List for 24 weeks, then offered a guided exercise program for 12 weeks

06

What researchers measure

Primary outcomes

  1. Feasibility of the exercise program (Retention)

    Percent of patients that complete the intervention

    Time frame: up to 24 weeks after start of intervention

  2. Feasibility of the exercise program (Adherence)

    Percent of patients that complete the exercise sessions

    Time frame: 12 weeks after start of intervention

  3. Feasibility of the exercise program (fidelity)

    Upon completion of the trial, a random sample of 10 recorded sessions will be analyzed for fidelity. Research staff who did not conduct the intervention will use a "fidelity checklist" of specific exercises and intervention characteristics (e.g., allowing time for questions, cueing for proper posture and form, etc.) required for each exercise session..

    Time frame: 12 weeks after start of intervention

  4. Satisfaction of program

    14-item scale measuring ease of use, convenience, engagement, enjoyment, and privacy elements of the intervention.

    Time frame: up to 24 weeks after start of intervention

  5. Affective attitude

    36-item scale assessing views, attitude, and experiences in exercise87

    Time frame: up to 24 weeks after start of intervention

  6. Perceived burden

    Single item, "Now that you've completed this part of the study, how burdensome or difficult did you find the experience. Select the response that best represents your experience." (1= Very burdensome to 5= Not too burdensome.)

    Time frame: up to 24 weeks after start of intervention

  7. Outcome expectation

    15-item scale assessing physical, social, and self-evaluative outcomes of exercise

    Time frame: up to 24 weeks after start of intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 31 months is close to that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Oct 25, 2023
StartActual
May 28, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06100263
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
May 28, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Feb 10, 2026

Study contacts

Cancer AnswerLine
Contact
CancerAnswerLine@med.umich.edu
1-800-865-1125
Angela Fong, PhD
principal investigator · University of Michigan Rogel Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion